Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cardiomyopathy
Biotech
Bayer pays $310M for Europe rights to BridgeBio's Vyndaqel rival
With the FDA mulling whether to approve acoramidis as a rival to Pfizer’s Vyndaqel, Bayer is paying $310 million to scoop up the European rights.
James Waldron
Mar 4, 2024 8:22am
Cytokinetics not in sale process, CEO says
Feb 28, 2024 11:25am
AstraZeneca's heart disease trial hits, teeing up Pfizer clash
Feb 2, 2024 6:43am
Novartis backs out of Cytokinetics deal: reports
Jan 12, 2024 5:26am
Applied Therapeutics fails heart disease phase 3, seeks partner
Jan 5, 2024 8:03am
Cytokinetics' heart failure drug improves exercise capacity
Dec 27, 2023 8:43am